Dr. Michael A Thompson
Claim this profileAurora Cancer Care-Milwaukee West
Studies Multiple Myeloma
Studies Plasma Cell Neoplasm
12 reported clinical trials
29 drugs studied
Area of expertise
1Multiple Myeloma
Stage I
Stage II
Stage III
2Plasma Cell Neoplasm
Stage I
Stage II
Stage III
Affiliated Hospitals
Clinical Trials Michael A Thompson is currently running
Combination Therapy
for Multiple Myeloma
This phase III trial compares the combination of four drugs (daratumumab, bortezomib, lenalidomide and dexamethasone) to the use of a three drug combination (daratumumab, lenalidomide and dexamethasone). Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as lenalidomide, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response and are used with other drugs in the treatment of some types of cancer. Adding bortezomib to daratumumab, lenalidomide, and dexamethasone may be more effective in shrinking the cancer or preventing it from returning, compared to continuing on daratumumab, lenalidomide, and dexamethasone.
Recruiting2 awards Phase 332 criteria
Belantamab Mafodotin
for Multiple Myeloma
The purpose of this study is to assess the pharmacokinetics (PK), safety, and tolerability of belantamab mafodotin monotherapy in Relapsed/Refractory Multiple Myeloma (RRMM) participants with impaired hepatic function and in matched RRMM participants with normal hepatic function.
Recruiting1 award Phase 111 criteria
More about Michael A Thompson
Clinical Trial Related4 years of experience running clinical trials · Led 12 trials as a Principal Investigator · 7 Active Clinical TrialsTreatments Michael A Thompson has experience with
- Lenalidomide
- Dexamethasone
- Biospecimen Collection
- Daratumumab
- Belantamab Mafodotin
- Belantamab Mafodotin
Breakdown of trials Michael A Thompson has run
Multiple Myeloma
Plasma Cell Neoplasm
Cancer
Kidney Failure
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael A Thompson specialize in?
Michael A Thompson focuses on Multiple Myeloma and Plasma Cell Neoplasm. In particular, much of their work with Multiple Myeloma has involved Stage I patients, or patients who are Stage II.
Is Michael A Thompson currently recruiting for clinical trials?
Yes, Michael A Thompson is currently recruiting for 6 clinical trials in Wauwatosa Wisconsin. If you're interested in participating, you should apply.
Are there any treatments that Michael A Thompson has studied deeply?
Yes, Michael A Thompson has studied treatments such as Lenalidomide, Dexamethasone, Biospecimen Collection.
What is the best way to schedule an appointment with Michael A Thompson?
Apply for one of the trials that Michael A Thompson is conducting.
What is the office address of Michael A Thompson?
The office of Michael A Thompson is located at: Aurora Cancer Care-Milwaukee West, Wauwatosa, Wisconsin 53226 United States. This is the address for their practice at the Aurora Cancer Care-Milwaukee West.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.